Results 201 to 210 of about 24,348 (233)

Autoantibodies in COVID-19 convalescent plasma donors. [PDF]

Vox Sang
Jazbec Gradišar K, Žiberna K, Mali P, Marić I, Rožman P, Maličev E.   +5 more
europepmc   +1 more source

Time-Dependent Outcomes of Convalescent Plasma in Early COVID-19: A Single-Center Cohort with a Host-Pathogen Perspective. [PDF]

Pathogens
Kalinowska K, Bociąga P, Wiatrak B.
europepmc   +1 more source

Categorization of rheumatoid arthritis into mild, moderate, and severe conditions to discriminate specificity and sensitivity of routine diagnostic serum biomarkers. [PDF]

Ann Med Surg (Lond)
Sharma P, Koundal P, Aggarwal J, Mohammed SA, Aman S, Bibi A.   +5 more
europepmc   +1 more source

Mass spectrometry-based analysis of rheumatoid factor. [PDF]

Front Immunol
De Leeuw J, Michiels B, Derua R, Dehaemers T, Dillaerts D, Cockx M, Frans G, Carpentier SC, Verschueren P, Bossuyt X.   +9 more
europepmc   +1 more source

Identification of key factors for early detection of rheumatoid arthritis in primary care using machine learning. [PDF]

Sci Rep
Rahimi F, Rajaei E, Movafagh N, Hadianfard AM.   +3 more
europepmc   +1 more source

Diagnostic value of anti-CCP test for rheumatoid arthritis

Reumatizam, 2005
Tešija Kuna, Andrea, Topić, Elizabeta, Šimundić, Ana-Maria, Grazio, Simeon, Perić, Porin, Stipić Marković, Asja   +5 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Anti-CCP biosensors in rheumatoid arthritis

Clinica Chimica Acta
Biosensors are unique analytical tools for the detection of biomarkers. Of these, autoantibodies against citrullinated proteins (ACPA) are useful for the differential diagnosis of rheumatoid arthritis (RA). The autoantibodies may be detected by immunoassay technology using synthetic cyclic citrullinated peptides (CCP), ie, anti-CCP.
Pari Karami, Danial Gholamin, Farzaneh Fathi, Taha Afsar, Mohammad Johari-Ahar   +4 more
openaire   +2 more sources

Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis

Clinical Rheumatology, 2006
Our aim is to assess the prevalence and associated clinical features of anti-CCP (cyclic citrullinated peptide) antibodies for RF (rheumatoid factor)-positive and RF-negative rheumatoid arthritis (RA) and psoriatic arthritis (PsA). In a prospective, cross-sectional, multi-centre study, we determined the titres of anti-CCP antibodies in 208 RA patients (
İNANÇ, Murat, DİRESKENELİ, RAFİ HANER, Elbir, Y., Kasapoglu-Gunal, E., Kamali, S., Dalkilic, E., İNANÇ, Murat   +6 more
openaire   +3 more sources

Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper

Autoimmunity Reviews, 2010
Rheumatoid arthritis (RA) is a crippling joint disease affecting over 20 million people worldwide. The cause of RA is most probably linked to the triad of microbial trigger, genetic association and autoimmunity and can be explained using the philosophical method of Karl Popper or Popperian sequences.
Ebringer, Alan, Rashid, Taha, Wilson, Clyde   +2 more
openaire   +3 more sources

Anti-cyclic citrullinated peptide (anti-CCP) antibodies with brucellosis

Rheumatology International, 2013
Anti-cyclic citrullinated peptide (anti-CCP) was positive in 11.5 % and rheumatoid factor was positive in 8.8 % of the patients with Brucella. After a comparative evaluation, we have found out that there was not a statistical significance concerning the anti-CCP levels between the patients with brucellosis and healthy control.
Pehlivan, YAVUZ, Onat, Ahmet Mesut, Sayarlioglu, Mehmet, Devay, Seda Duygulu, Aydinli, Musa, Mercan, Ozge Kaya, Ugurlu, Kenan, Dag, Muhammet Said, Kisacik, Bunyamin   +8 more
openaire   +3 more sources